Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai Europe, the UK-based subsidiary of Eisai Co, has received positive opinion from the scientific committee of the European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP) for its anti cancer drug Halaven.
Subscribe to our email newsletter
Eisai said the drug has got the positive opinion as a monotherapy indicated in the treatment of patients with locally advanced or metastatic breast cancer who have received at least two chemotherapeutic regimens, including an anthracycline and a taxane.
CHMP’s decision was based on the positive results from a Phase III EMBRACE study, which showed an overall survival (OS) benefit for patients treated with Halaven of 2.7 months compared with TPC (13.2 months versus 10.5 months, hazard ratio 0.805, nominal p=0.014).